Cannabix Technologies Provides Update on Marijuana Breathalyzer Development
17 February 2017 - 12:30AM
InvestorsHub NewsWire
7934 Government Road, Burnaby, B.C.,
V5A 2E2
Phone: (604) 551-7831
Fax: 604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
The Cannabix Marijuana Breathalyzer is being
developed to give law enforcement and employers a tool to enforce
public safety as Canada gets set to table marijuana legalization
this spring
Vancouver, BC -- February 16, 2017 --
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC
PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix
Marijuana Breathalyzer for law enforcement and the workplace, is
pleased to provide a development update on its
FAIMS Beta 2.0 (field asymmetric waveform ion
mobility spectrometry) based marijuana breathalyzer for the
detection of 9-tetrahydrocannabinol (“THC”) in human breath.
Development in Gainesville, Florida and Vancouver, BC is
progressing well and the Company expects to begin pre-trial live
subject testing during the month of March.
Since introducing the Beta 2.0 version of the
Cannabix Marijuana Breathalyzer in late 2016, Company scientists
have been engaged in developmental testing, method development, and
continuously improving the design of the device. At the same
time, experiments have been done with THC to characterize the
individual parts of the instrument and improve the efficiency of
human breath collection and sampling.
The Cannabix Marijuana Breathalyzer consists of
proprietary components including a generator enabled by the latest
chip technology to provide extremely fast high-voltage square wave
transitions that significantly improve chemical separations, and a
novel plasma ionization source that provides efficient ionization
with a relatively small footprint. The Company anticipates
completing developmental testing of the Beta 2.0 device within the
next month while preparing for preliminary human subject
testing.
Various technical leaps have been made with
several components over the last 3 months. In particular, the
dielectric barrier discharge ionization source (“DBD”) which allows
efficient ionization with relatively low voltages, has been
significantly optimized in every aspect of the source (sizes,
geometries, and materials) leading to significantly smaller
instrument footprint. In addition, the high-voltage square wave
generator (“HVSW”) which causes ions to oscillate rapidly at a high
frequency between the FAIMS electrodes, to create separation from
each other, has been drastically improved.
The Company is working with its Vancouver based
engineering firm to ruggedize and refine its breath collection
component (i.e. the collection tube where users breathe into the
breathalyzer). In particular, engineers are testing a very exciting
proprietary flow-through heat exchanger technology that stabilizes
breath temperature in extreme cold as well as humid temperature
settings.
In December, a special Task Force set up by the
Government of Canada to review the future regulation of
recreational cannabis in Canada, issued a report, where the among
other things, emphasised the issue of marijuana impaired driving as
a critical issue and presented a host of specific recommendations
to provincial Ministers across Canada, including:
Supporting the development of an appropriate roadside drug
screening device for detecting THC levels, and invest in these
tools;
Determining whether to establish a per se limit as part of a
comprehensive approach to cannabis-impaired driving and re-examine
per se limits should a reliable correlation between THC levels and
impairment be established;
Investing in baseline data collection and ongoing surveillance
and evaluation in collaboration with provinces and
territories.
The Government of Canada, is expected to table marijuana
legalization legislation in the spring. The Company will use key
metrics and guidance from Drugs and Driving Committee (DDC), which
is an advisory body to the Canadian Department of Justice on issues
relating to drug-impaired driving and has been given a mandate to
develop reports regarding drugs that are proposed for
zero-tolerance and per se legislation, including cannabis.
About Cannabix Technologies
Inc.
Cannabix Technologies Inc. is a leader in
marijuana breathalyzer development for law enforcement and the
workplace. Cannabix has established breath testing technologies in
the pursuit of bringing durable, portable hand-held tools to market
to enhance detection of marijuana impaired driving offences on
roads at a time when marijuana is becoming legal in many global
jurisdictions. Cannabix is working to develop drug-testing devices
that will detect THC- the psychoactive component of marijuana that
causes intoxication- using breath samples. In particular, Cannabix
is focused on developing breath testing devices for detection of
recent use of THC, in contrast to urine testing for THC metabolite
that requires an invasive collection and reflects use days or even
weeks earlier. The devices will also be useful for other practical
applications such as testing employees in the workplace where
intoxication by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company
at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept
responsibility for the adequacy or accuracy of this
release.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains
forward-looking information that involves various risks and
uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company’s plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (v) the ability of the Company to develop and market
its future product; and (vi) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Apr 2024 to May 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From May 2023 to May 2024